Universitaetsklinikum Erlangen AöR
- Address
- lock Available on a paid plan
Oncology at Universitaetsklinikum Erlangen AöR
The clinical research here is centered on neoplasms, with studies focused on cancer and large B-cell lymphoma. These trials are designed to explore new treatment options and assess how well emerging therapies perform in people with blood-related cancers.
- Evaluating new treatment strategies for large B-cell lymphoma
- Comparing the effectiveness of combination approaches in cancer care
- Assessing safety and tolerability of oncology treatments
With 5 trials and 81 investigators contributing, Medizinische Klinik 5 supports focused research aimed at improving outcomes for patients with difficult-to-treat malignancies.
Hematologic Cancer Research
The site is also active in studies of blood cancers, especially large B-cell lymphoma, where researchers are testing whether new combinations can improve disease control and extend the time before the disease worsens.
- Testing combination therapy for newly diagnosed large B-cell lymphoma
- Measuring treatment effectiveness through progression-free survival
- Supporting development of more effective lymphoma therapies
This work reflects a strong clinical focus on refining care for patients with aggressive hematologic malignancies.
Therapy Continuation and Safety Studies
Another part of the research portfolio involves follow-up studies that look at whether ongoing treatment remains safe and appropriate for patients who have already received therapy in other studies.
- Continuing darolutamide treatment in eligible participants
- Monitoring treatment safety over time
- Supporting long-term care decisions in oncology
At Universitaetsklinikum Erlangen AöR, these studies help build a clearer picture of how cancer treatments perform beyond initial use, with attention to both benefit and safety.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 23 therapeutic areas and 15 of 477 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 457 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 110 by active trials.
- 1Novartis Pharma AG10active
lock +109 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB22trials
lock +63 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Universitaetsklinikum Erlangen AöR
lock Showing 1 of 394 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (20321) An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer sponsored studies | Bayer Consumer Care AG | Phase III | Not Recruiting | Oct 2020 | — |
IMP list
lock Showing 1 of 477 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 30 | Unknown | 2017-03-07 | 2026-07-14 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.